TET2 and acute myeloid leukemia: Notably, NRAS, SMC1A, SMC3 and RAD21 mutations have been reported to have no effect on the prognosis of patients with AML 36, 37 In addition, the methylation of TET2 and FLT3 improved the prognosis of patients with AML 27.